IFNG and neoplasm: Interleukin 12 (IL-12) is an ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) responses and to potently stimulate the production of IFN-γ leading to a potentially effective anticancer defense [4,5].